President Trump faces a bipartisan challenge to his Iran military campaign while congressional leaders move to block a White House plan to politicize the NIH grant process.
The delicate balance of power between the executive and legislative branches is facing its most significant test of the current term as President Donald Trump asserts broad authority over both foreign military operations and the domestic administrative state. In the halls of the Senate, a coalition led by Senator Andy Kim (D-N.J.) is preparing to force a vote as early as this week on a War Powers Resolution aimed at terminating U.S. involvement in hostilities with Iran. This legislative maneuver follows a House resolution that passed 220–204, a vote notable for the seven Republicans who broke ranks to join Democrats, signaling a widening fissure within the GOP over the limits of Article II authority.
The White House has remained steadfast, citing the 1973 War Powers Resolution as the legal basis for the President to continue the campaign without further congressional consent. However, the political math in the Senate remains complex. With Senator John Fetterman (D-Pa.) expected to oppose the measure, proponents likely need five Republican senators to secure passage. Figures such as Susan Collins, Lisa Murkowski, Rand Paul, and Bill Cassidy have previously shown a willingness to challenge the administration on this front, reflecting a growing unease among constitutionalists who view the prolonged conflict as a departure from the legislature’s sole power to declare war.
Domestically, the administration is opening a second front in the battle for bureaucratic control. President Trump has directed OMB Director Russell Vought to draft an executive order that would establish a political review board for National Institutes of Health (NIH) grants. This proposed board, which would include Vought and NIH Director Jay Bhattacharya, would oversee a research portfolio valued at approximately $48 billion. Reports indicate that the board could require unanimous approval for grant awards, effectively granting a single political appointee the power to veto scientific research. This move reportedly stems from White House objections to specific funding decisions involving Harvard researchers.
This push for centralized control has met fierce resistance from the very lawmakers who control the federal purse strings. Senate Appropriations Chair Susan Collins and Vice Chair Patty Murray have warned that such political interference violates the fundamental principle of merit-based grantmaking. Collins pointedly noted that a stopgap funding law signed on September 2 specifically blocks the OMB from implementing this grant rule or any “substantially similar” approach. The conflict has also created internal friction within the administration, as Dr. Bhattacharya is reportedly resisting Vought’s efforts to impose political filters on scientific inquiry.
Beyond these structural disputes, the administration is aggressively utilizing executive actions to address economic pressures. The recent extension of the “Most Favored Nation” drug-pricing model to all 50 state Medicaid programs represents a massive shift in healthcare policy. While the administration projects $64.3 billion in savings over a decade, the program is shrouded in uncertainty. As of late September, only 40 states and Puerto Rico have signed formal agreements, and the lack of a definitive list of covered medicines has left both drugmakers and state governors in a regulatory limbo.
As diesel prices climb above $6 per gallon in 49 states—reaching a staggering $8.42 in California—the administration’s reliance on executive orders and Article II justifications appears to be a response to a gridlocked Congress. Yet, for those who value the traditional Virginian perspective on limited executive power, these developments represent a concerning expansion of the administrative state. Whether through the redirection of scientific funds or the conduct of undeclared wars, the current trajectory suggests a presidency determined to bypass the “Beltway bubble” by testing the very boundaries of constitutional law.
